Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

Bladder cancer is the ninth most common cancer worldwide, and the number of diagnosed incident cases is set to increase.

A bladder ultrasound gives providers clues about how the bladder expands and holds urine. This article lists conditions ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...

Eligible patients had T2-T4a muscle-invasive bladder cancer and were randomized 1:1:2 to standard WBRT, SART, or DART. Within each randomized group, investigators assigned patients to two ...

This study included a review of consecutive patients diagnosed with NMIBC between January 2005 and May 2023 to identify ...

The FDA is currently evaluating the application of intravesical mitomycin for low-grade intermediate-risk non–muscle-invasive bladder cancer.

In a phase 1 trial in patients with non-muscle invasive bladder cancer, Aura’s viruslike drug conjugate (VDC) bel-sar—along with infrared light activation—completely eradicated the tumors of ...

Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

UroGen Pharma has reported its financial results for the third quarter of 2024, highlighting the FDA’s acceptance of its New Drug Application for UGN-102, a potential breakthrough treatment for ...